Equities

Zynex Inc

ZYXI:NSQ

Zynex Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)8.26
  • Today's Change0.150 / 1.85%
  • Shares traded63.59k
  • 1 Year change-9.03%
  • Beta0.5026
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Zynex Inc had net income fall -42.91% from 17.05m to 9.73m despite a 16.54% increase in revenues from 158.17m to 184.32m. An increase in the selling, general and administrative costs as a percentage of sales from 60.93% to 68.46% was a component in the falling net income despite rising revenues.
Gross margin80.20%
Net profit margin2.49%
Operating margin4.57%
Return on assets3.48%
Return on equity10.23%
Return on investment4.06%
More ▼

Cash flow in USDView more

In 2023, Zynex Inc increased its cash reserves by 121.30%, or 24.44m. The company earned 17.76m from its operations for a Cash Flow Margin of 9.63%. In addition the company generated 7.65m cash from financing while 966.00k was spent on investing.
Cash flow per share0.2853
Price/Cash flow per share27.62
Book value per share1.11
Tangible book value per share0.2441
More ▼

Balance sheet in USDView more

Zynex Inc has a Debt to Total Capital ratio of 62.46%, a lower figure than the previous year's 98.75%.
Current ratio3.94
Quick ratio3.15
Total debt/total equity1.66
Total debt/total capital0.6246
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -38.20%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)1.09
EPS (TTM) vs
TTM 1 year ago
-65.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.